GovBidAlerts
OpenSolicitationFederal

Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination

Department of Defense · Defense Health Agency (dha)

Due Closes in 2 daysRef. HT9427-26-R-E020

At a glance

What

This RPP is being issued by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency’s Portfolio Acquisition Executive (PAE) Medical Products (MP) Warfighter Protection (WPAC) & Acute Care Program…

Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (NAICS 541715)

Who can bid
Any business — no set-aside listed
Where
Frederick, MD
Key dates
  • Posted: Nov 12, 2026
  • Deadline: Fri, Nov 20, 2026 · 12:00 PM EST (closes in 2 days)
How to respond

Bryan Heickman · bryan.g.heickman.civ@health.mil

Submit per the instructions on SAM.gov ↗

Documents
None attached here — check SAM.gov

Description

This RPP is being issued by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency’s Portfolio Acquisition Executive (PAE) Medical Products (MP) Warfighter Protection (WPAC) & Acute Care Program Management Office (PMO) Care located in Frederick, Maryland at Fort Detrick. The Warfighter Protection and Acute Care Project Management Office (WPAC PMO) has a requirement for the development of a Barrier Combination product. The Barrier Combination product is defined as being composed of both a physical barrier to protect a wound and an antibacterial and/or antifungal activity released from the barrier to prevent the spread of organisms and avoid systemic infections. This RPP will result in one award to develop the Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination (BC) prototype product.
Read more ↓
The final product MUST be a combination wound treatment that includes a barrier component that is either infused or impregnated with antimicrobial and/or antifungal properties and have U.S. Food Drug Administration (FDA) approval (or clearance). The award, as a result of this RPP, will be awarded under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022. NOTE: Another amendment will be posted which will include Offeror questions and Government responses. (Amendment 0003 only extends the proposal due date). Amendment 0001 – removed alternate point of contact information under “Contract Information” on SAM.gov Amendment 0002 – revised proposal due date from: 12:00pm eastern, Friday, 23 Oct 2026 to: 12:00pm eastern Friday, 06 Nov 2026 Amendment 0003 – revised proposal due date from: 12:00pm eastern Friday, 06 Nov 2026 to: 12:00pm eastern Friday, 20 Nov 2026 Amendment 0004 – Incorporates Attachment J - Offeror questions & Government responses, Updates RPP, Attachment A – SOO, Attachment E- Draft Agreement Terms & Conditions, Attachment H – SOW Template, and adds Attachment K – CMMC Level I Self-Assessment Instructions.

Other notices in this solicitation

All notice detailsShow ↓
Solicitation number
HT9427-26-R-E020
Notice type
Solicitation
Product/service code (PSC)
AN13
Department
Department of Defense
Sub-agency
Defense Health Agency (dha)
Contracting office
DEFENSE HEALTH AGENCY
Office location
FORT DETRICK, MD, 21702
Place of performance
Frederick, MD
Archive date
Dec 5, 2026

Contacts